Levomethadyl Acetate

Jump to: navigation, search
Levomethadyl Acetate
LAAM.png
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Pharmacokinetic data
Protein binding~80%
MetabolismCYP3A4
Elimination half-life2.6 days
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H31NO2
Molar mass353.50

Overview

Levomethadyl acetate, also known as levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites. It was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. In 2001, the product ORLAAM was removed from the European market due to reports of severe cardiac-related adverse events. In 2003, Roxane Laboratories, Inc. discontinued ORLAAM in the US.[1]

Indications

LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine. LAAM is not approved for use in Canada.

Chemistry and Pharmacology

Levomethadyl acetate is the levo isomer of α-methadyl acetate. The dextro isomer is more potent but shorter acting. The levo isomer is also less toxic with an LD50 in mice of 110mg/kg s.c. and 172.8mg/kg orally as opposed to LD50s of 61mg/kg s.c. and 118.3mg/kg orally for dl-α-methadyl acetate. It has a melting point of 215°C and a molecular weight of 353.50. β-methadyl acetate also exists, however it is more toxic and less active than α-methadyl acetate and has no current medical use.

Levomethadyl acetate undergoes extensive first-pass metabolism to the active demethylated metabolite nor-LAAM, which is further demethylated to a second active metabolite, dinor-LAAM. These metabolites are more potent than the parent drug.

Dosing

LAAM is used as an oral solution of levomethadyl acetate hydrochloride at a concentration of 10mg/mL in bottles of 120 and 500 mL under the brand name ORLAAM. The first dose of LAAM for patients who have not started treatment with methadone is 20-40mg. The first dose for patients who have been receiving methadone will be a little higher than the amount of methadone that was being taken every day, but not more than 120 mg. Afterwards, the dosage may be adjusted as needed. Unlike methadone, which requires daily administration, LAAM is administered three times a week.

References

External links



Linked-in.jpg